Author Archives: Marisa Wexler MS

Cholinesterase Inhibitors Alone Can Ease LEMS Symptoms, Per Report

Cholinesterase inhibitors may be useful in controlling the symptoms of Lambert-Eaton myasthenic syndrome (LEMS) in people with relatively mild disease, as highlighted in a recent case report. The findings suggest that these medications may be particularly useful for managing LEMS in countries where Firdapse (amifampridine) — the…

Jacobus Recalls 3 Lots of Ruzurgi Due to Contamination

Jacobus Pharmaceutical has issued a voluntary recall for three lots of Ruzurgi (amifampridine), a medication that is approved in the U.S. to treat people with Lambert-Eaton myasthenic syndrome (LEMS) ages 6–17. According to the company’s announcement, while doing confirmatory full testing on one of the lots, control…

Report: Use Multiple Tests to Find LEMS Antibodies

Immunofluorescence, a technique that can be used to detect antibodies associated with Lambert-Eaton myasthenic syndrome (LEMS), was negative in a 72-year-old woman, but another technique — called immunoblot — was positive for LEMS-associated antibodies. This ultimately allowed for a LEMS diagnosis and the discovery of a previously unknown tumor.

2nd Firdapse Patent Secured in US by Catalyst with 3 Still Pending

Catalyst Pharmaceuticals has secured a second U.S. patent covering Firdapse (amifampridine), an approved oral treatment for Lambert-Eaton myasthenic syndrome (LEMS). “We are pleased that this second patent for Firdapse has been issued and believe that it further enhances our intellectual property protection for Firdapse,” Patrick J. McEnany, chairman…

Catalyst, DyDo Strike Deal to Develop, Market Firdapse in Japan

Catalyst Pharmaceuticals has teamed up with DyDo Pharma to develop and commercialize Firdapse (amifampridine) in Japan for the treatment of Lambert-Eaton myasthenic syndrome (LEMS). Under the terms of their agreement, DyDo will be responsible for funding all clinical, regulatory, marketing, and commercialization activities in Japan. In turn,…

LEMS Likely Triggered by Rare Skin Cancer in Case Study

Lambert-Eaton myasthenic syndrome (LEMS) may be associated with a rare type of skin cancer called Merkel cell carcinoma (MCC), according to a case study which also highlighted the need for multidisciplinary care in such complex cases. The case report, “Lambert-Eaton Myasthenic Syndrome and Paraneoplastic Cerebellar Degeneration…

Canadian Agency Suggests Ruzurgi Be Reimbursed With Conditions

The Canadian Agency for Drugs and Technologies in Health (CADTH) has recommended that Ruzurgi (amifampridine) be reimbursed for the treatment of Lambert-Eaton myasthenic syndrome (LEMS) in individuals 6 and older, but only if certain conditions are met. These include patients for whom the medication has been prescribed by…